ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2572

Molecular Signatures in SLE: Flare Vs. Infection

Meggan Mackay1, Michaela Oswald2, Jorge Sanchez-Guerrero3, Juan J. Lichuaco4, Cynthia Aranow5, Sean Kotkin6, Peter K. Gregersen7 and Betty Diamond8, 1Autoimmune & Musculoskeletal Disease, Feinstein Institute for Medical Research, Manhasset, NY, 2Laboratory of Genomics and Human Genetics, The Feinstein Institute for Medical Research, Manhasset, NY, 3UHN Toronto Western Hospital, Toronto, ON, Canada, 4Medicine, St. Luke's Medical Center, Quezon City, Philippines, 5Feinstein Institute for Medical Research, Manhasset, NY, 6Autoimmune & Musculoskeletal Disease, The Feinstein Institute for Medical Research, Manhasset, NY, 7Genomics and Human Genetics, The Feinstein Institute for Medical Research, Manhasset, NY, 8Autoimmune & Musculoskeletal, Feinstein Institute Med Rsch, Manhasset, NY

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: infection and systemic lupus erythematosus (SLE), RNA

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: ACR/REF Edmond L. Dubois, MD Memorial Lectureship: Hydroxychloroquine Reduces Thrombosis in Systemic Lupus Erythematosus, Particularly in Antiphospholipid Positive Patients

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Inability to distinguish between infection and the inflammatory response related to SLE disease activity using clinical judgment often compromises timely and effective treatment.  Gene expression profiling of circulating leukocytes has been used to differentiate between malignancy subtypes and between sepsis and sterile inflammation. The “IFN signature” in SLE has been linked to disease pathogenesis and disease activity. A biomarker that precisely and rapidly distinguishes between active disease and infection would allow for more directed therapy, resulting in improved outcomes. RNA microarray analysis of peripheral blood leukocytes in acutely ill SLE patients was used to identify gene expression profiles that distinguish the host response to infection from inflammation related to active disease.

Methods:

37 SLE patients with suspected infection or active SLE were recruited from 3 centers in New York, Mexico and the Philippines. Subjects were excluded for pregnancy, a history of infection with Hepatitis B, C, HIV or if treatment had been initiated for the current illness. Whole blood was collected in Tempus™ Blood RNA Tubes and disease activity (SELENA SLEDAI) was measured at the time of enrollment. Infection determination was based on results of cultures, viral antibodies or PCR analyses. Microarray analyses were performed on the Illumina HT12v4 platform. Gene expression data were grouped using a modular analysis framework for blood genomics that has been applied to SLE previously (Immunity.2008; 29:150). Clinical characteristics were summarized using appropriate descriptive statistics with correction for multiple comparisons. Statistical significance for microarray modules was determined using a hypergeometric test.

Results:

31 subjects had adequate RNA for analysis; 19 met criteria for infection and subjects were grouped as either infection or flare as the cause of acute illness. There were no significant group differences in age, disease duration, ethnicity, co-morbid states, history of prior CNS or renal disease or current medication use. Presence of low serum complement or high anti-dsDNA antibody titers did not distinguish between groups, however, SLEDAI scores were significantly higher with disease activity (p=0.002). Flare subjects exhibited significant over expression of genes encoding immunoglobulin chains and CD38 (plasma cell module; p=0.001) and IFN inducible genes (p<.000). Subjects with infection demonstrated significant over expression of genes encoding molecules expressed by cells of myeloid lineage (p=0.018) and molecules inducible by or inducing inflammation (inflammation II module; p=.012).

Conclusion:

We have identified gene expression signatures that associate significantly with either infection or disease activity. Not surprisingly, genes over expressed in flare are those associated with plasma cells or are IFN inducible. Genes expressed in response to infection encode molecules such as FcγRIIA, CD86, CD163 and others associated with pattern recognition such as CD14, TLR2, MYD88, TNFR2 and BAFF. While SLEDAI scores correlate with disease activity, identification of a “sepsis signature” provides a more objective and reliable premise for treatment.


Disclosure:

M. Mackay,
None;

M. Oswald,
None;

J. Sanchez-Guerrero,
None;

J. J. Lichuaco,
None;

C. Aranow,
None;

S. Kotkin,
None;

P. K. Gregersen,
None;

B. Diamond,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/molecular-signatures-in-sle-flare-vs-infection/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology